ClinicalTrials.gov
public full text
Public Domain
Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
This phase I trial studies the side effects and best dose of cellular immunotherapy in treating patients with high-risk acute lymphoblastic leukemia. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer#1127227
- Haploidentical NK-cell Infusion in Acute Myeloid Leukemia#851022
- Leveraging Immunotherapy in Acute Myeloid Leukemia Treatment: Opportunities and Challenges.#404437
- Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells#226270
- Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia#268555
Record · ID 1060721
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive